Q3 2026 results · 28 October 2026

GSK's specialty medicines grew 15% at CER to $5.2bn, 44% of sales.

$5.2Bspecialty medicines, up 15% at CER

$11.9Bsales, up 5% at constant currency

55%of sales made in the US

Source

Get a note when GSK reports next.

Whatco sends a short notification with the number that matters, and the full story of the company is a tap away.